Drug Topics
OCTOBER 15, 2024
The financial burden of in vitro fertilization (IVF) medications has become increasingly prohibitive, limiting the availability of fertility treatments for many.
PharmaVoice
OCTOBER 15, 2024
A Nobel Prize in chemistry for Google’s DeepMind protein-structure mapping is the tip of the iceberg for advances in drug discovery and development.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Topics
OCTOBER 15, 2024
In a systematic review, researchers explored the role of clinical pharmacists within a multidisciplinary team treating patients with inflammatory bowel disease.
Fierce Healthcare
OCTOBER 15, 2024
Walgreens reported a loss of $3 billion in the fourth quarter and plans to close 1,200 stores over the next three years as part of the retail drugstore chain's ongoing turnaround strategy amid a ro | Walgreens reported a loss of $3 billion in the fourth quarter and plans to close 1,200 stores over the next three years as part of the retail drugstore chain's ongoing turnaround strategy amid a rocky fiscal 2024.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Drug Topics
OCTOBER 15, 2024
David Pope, PharmD, Chief Pharmacy Officer at XiPhin, shared his thoughts on value-based care and how it is used within a pharmacy setting.
PharmaVoice
OCTOBER 15, 2024
Data readouts over the next six months could set expectations for how the highly lucrative market for weight loss therapies will look in the future.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
STAT
OCTOBER 15, 2024
You’re reading the web version of Health Care Inc., STAT’s weekly newsletter following the flow of money in medicine. Sign up to get it in your inbox every Monday. Hello, you spry bunch. We’re coming to you on a Tuesday after yesterday’s holiday. What are you looking to read more about as the year winds down? Let us know: bob.herman@statnews.com.
Drug Topics
OCTOBER 15, 2024
The first-line B/F/TAF regiment was evaluated in Hispanic/Latino patients, as well as in those with chronic kidney disease.
STAT
OCTOBER 15, 2024
On Sept. 26, the FDA approved the first truly new antipsychotic in decades: Cobenfy. In clinical trials, it didn’t cause certain side effects that traditionally interfere with medication adherence, including weight gain, lethargy, and movement disorders. I have schizoaffective disorder, bipolar type — a combination of schizophrenia and bipolar disorder — and I agree that this is a monumental development for my community.
Drug Topics
OCTOBER 15, 2024
Research from ESMO 2024 focused on the relationship between survival outcomes and medication adherence.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
STAT
OCTOBER 15, 2024
It was a dramatic call to action by the American Heart Association: The organization declared its decade-long goal culminating in 2020 was to slash deaths from cardiovascular disease and stroke by 20%. It also promised in its scientific journal to move all Americans toward “ideal cardiovascular health.” That never happened. Deaths did decrease by 15% from 2010, but it was a “disappointment” that fatalities linked to conditions like high blood pressure, heart failure,
Drug Topics
OCTOBER 15, 2024
Drug Topics sat down with Adam J. James, PharmD, to discuss learnings from his extensive experience at Rite Aid.
STAT
OCTOBER 15, 2024
In the early days of the Covid-19 pandemic, hospitals were desperate for ways to manage the flood of seriously ill patients. Many turned to an artificial intelligence algorithm developed by Epic Systems , the electronic health record company, to predict which patients were most likely to rapidly deteriorate so they could get the critical care they needed.
Drug Topics
OCTOBER 15, 2024
On June 26, 2024, the FDA approved ensifentrine (Ohtuvayre) for the treatment of COPD.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Pharmacy Times
OCTOBER 15, 2024
Imuldosa has received approval for all indications of its reference product, including ulcerative colitis, psoriatic arthritis, and Crohn disease.
Fierce Healthcare
OCTOBER 15, 2024
Blue Cross Blue Shield plans have agreed to a $2.8 billion settlement to resolve legal allegations from a slew of providers who claim the insurers colluded to prevent competition and lower reimburs | Blue Cross Blue Shield plans have agreed to a $2.8 billion settlement to resolve legal allegations from a slew of providers who claim the insurers colluded to prevent competition and lower reimbursements.
STAT
OCTOBER 15, 2024
Why aren’t we doing better in the battle against cardiovascular disease? Over the last few months, STAT put that question to nearly a dozen experts in cardiology, primary care, endocrinology, and vascular disease. Nearly all of them, as a related article details, pointed to a crisis in primary care.
Fierce Healthcare
OCTOBER 15, 2024
The Drug Enforcement Administration is poised to extend pandemic-era telehealth prescribi | The third temporary extension is rumored to be for just one year, punting the deadline for the next administration to negotiate permanent rules to December 2025. Telemedicine companies, including those that prescribe Adderall, will be able to continue prescribing as they have since 2020.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Pharmacy Times
OCTOBER 15, 2024
Legislative efforts in the states and Washington, DC, have made progress, but there is still a way to go.
Fierce Healthcare
OCTOBER 15, 2024
UnitedHealth Group kicked off another round of earnings calls for major health insurance companies Tuesday morning, when it
Pharmacy Is Right For Me
OCTOBER 15, 2024
Hello everyone, my name is Diana Martinez-Nava and I am a fourth-year student pharmacist at The University of New Mexico College of Pharmacy. I would like to take some time on this special month celebrating our Hispanic Heritage to share my story on my pharmacy journey. My interest in becoming a pharmacist began around the time I was 8 years old. I was that small child who could barely see over the counter at our neighborhood pharmacy next to my father’s arm who would be reaching out to collect,
Fierce Healthcare
OCTOBER 15, 2024
CareNu is starting to sign members up for health insurance through its Medicare Advantage plan for the first time. | CareNu's subsidiary is launching an Institutional Special Needs Medicare Advantage plan in Florida for patients with chronic illness.
Pharmacy Times
OCTOBER 15, 2024
Shirish Gadgeel, MD, discusses an integrated analysis of the regional TRUST-I study and global TRUST-II study presented at the European Society for Medical Oncology Congress 2024.
pharmaphorum
OCTOBER 15, 2024
GSK has filed lawsuits against Moderna, claiming infringement of patents covering mRNA vaccines for COVID-19 and RSV
Pharmacy Times
OCTOBER 15, 2024
Investigators state that health care providers should consider the potential use of 2 doses to increase the effectiveness against influenza B.
STAT
OCTOBER 15, 2024
You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life sciences. Sign up to get it delivered in your inbox every Tuesday and Thursday. Why nurses liked an AI bot more than doctors did An interesting research letter out in JAMA Network Open suggests attitudes toward large language models in health care could vary based on license and professional role.
pharmaphorum
OCTOBER 15, 2024
Transgene's therapeutic vaccine for cervical and anogenital cancers failed a phase 2 trial, but an efficacy signal warrants further study
STAT
OCTOBER 15, 2024
As Election Day 2024 gets closer, STAT’s First Opinion asked executives from leading biotech and pharmaceutical companies to reflect on how their industry is being portrayed in the presidential campaign — and what their hopes are for a new presidential administration. With all eyes currently on the upcoming U.S. elections, it’s easy to forget that this year more than 75 countries have headed to the polls or will soon.
pharmaphorum
OCTOBER 15, 2024
Health plans, employers, and healthcare providers plan to increase their spending on digital health technologies in the next 12 months, says PHTI survey
Outsourcing Pharma
OCTOBER 15, 2024
The big pharma company Sanofi has discontinued a phase 2 trial of U.S. partner Denali Therapeuticsâ oditrasertib for the treatment of multiple sclerosis after the drug failed to perform.
STAT
OCTOBER 15, 2024
Hello, everyone, and how are you today? We are doing just fine, thank you, especially after a lengthy weekend respite. Of course, we have returned to the usual routines, so we are firing up the trusty coffee kettle as we brace for another round of deadlines, online meetings, and the like. No doubt, you may relate. So please join us as we hoist our cup of stimulation — our choice today is cinnamon vanilla — and get cracking.
The Honest Apothecary
OCTOBER 15, 2024
Social media has managed to blur the lines between work life and home life. These days many of us are growing more comfortable openly sharing things about ourselves that might not normally be public knowledge to our co-workers or our boss. With just a few clicks our pals at work can be flipping through our […] The post Creepy, Stalking Bosses appeared first on The Honest Apothecary.
STAT
OCTOBER 15, 2024
Hello! Hope you had a restful and reflective Indigenous Peoples’ Day. Today, we talk about how the autoimmune disease space is hotter than ever, see more gene therapy contraction, and the CEO of a generics giant talks about how elections affect industry. The need-to-know this morning Johnson & Johnson reported third-quarter earnings. Investment in autoimmune disease is soaring Investment has surged this year in autoimmune disease: More than $1.7 billion has been committed to this spac
Expert insights. Personalized for you.
424 
Let's personalize your content